Latest 10-Q quarterly reports

Rumble Inc. reported a 7% increase in Q1 2026 revenue to $25.5 million, but its net loss widened significantly to $30.3 million.

GEN Restaurant Group reports a 6.0% revenue decrease in Q1 2026 compared to the prior year, alongside a widening net loss.

Co-Diagnostics reports a wider net loss for Q1 2026 due to increased R&D spending and lower other income, despite a rise in product revenue.

JFB Construction Holdings reported a significant increase in revenue for Q1 2026, driven by large real estate development projects, but experienced a substantial net loss.

Rhinebeck Bancorp, Inc. reported a marginal decrease in net income for the first quarter of 2026 compared to the prior year, with diluted EPS also slightly lower.

PEDEVCO Corp. reported a net loss for Q1 2026, impacted by significant derivative contract losses, despite a substantial increase in revenues driven by its October 2025 merger.

American Integrity Insurance Group reports Q1 2026 results with increased net premiums earned and a higher combined ratio.

GeoVax Labs reports reduced operating expenses and net loss in Q1 2026, with continued focus on vaccine development and ongoing capital raising efforts.

MetaVia Inc. reported a net loss of $3.8 million for Q1 2026, with operating expenses increasing slightly, while cash reserves remain a concern for ongoing operations.

Forward Industries, Inc. announced the appointment of Mark Brazier as Chief Financial Officer and reported significant revenue growth driven by its digital asset strategy, alongside substantial digital asset impairments.

Origin Materials, Inc. announced its Board of Directors has approved a plan for dissolution and liquidation, leading to a significant workforce reduction and cessation of operations.

Vuzix Corporation (VUZI) filed its Q1 2026 10-Q, detailing a revenue decrease driven by lower product sales, offset by growth in engineering services, while managing operational expenses and securing capital through its ATM program.

Medicus Pharma Ltd. reported a significant increase in net loss for Q1 2026, driven by higher operating expenses, while advancing its clinical pipeline and completing strategic acquisitions.

Nano Nuclear Energy Inc. reported a strong liquidity position with $568.7 million in cash and short-term investments as of March 31, 2026, while continuing significant investment in its microreactor technology.

ProCap Financial, Inc. reported a net loss of $107.8 million for Q1 2026, impacted by digital asset valuation changes, while also completing the acquisition of AI firm CFO Silvia.

Dynamix Corporation announced the termination of its Business Combination Agreement and subsequent receipt of $50 million, while continuing its search for a new target.

My Size, Inc. reported a 62% increase in revenue for Q1 2026 to $2.39 million, but also saw an expanded net loss of $1.48 million.

BullFrog AI Holdings, Inc. reports Q1 2026 results, highlighting increased cash reserves from equity financing, ongoing efforts to regain Nasdaq compliance, and continued R&D investment.

Axiom Intelligence Acquisition Corp 1 reports on its financial condition and operational activities for the quarter ended March 31, 2026, highlighting its ongoing search for a business combination.

Middleby Corporation's Q1 2026 report shows increased net sales driven by its Commercial Foodservice and Food Processing segments, alongside a significant strategic divestiture.

KalVista Pharmaceuticals reports Q1 2026 results, driven by EKTERLY sales, and announces a definitive agreement to be acquired by Chiesi for $27.00 per share.

Jasper Therapeutics reports a significant decrease in R&D expenses for Q1 2026, alongside a substantial increase in cash burn, while facing ongoing litigation and substantial doubt about its ability to continue as a going concern.

Veritone, Inc. reported a net loss of $19.5 million for Q1 2026, with significant decreases in revenue and a continued substantial doubt about its ability to continue as a going concern.

NioCorp Developments Ltd. reports significant cash increase and progress on Elk Creek Project, alongside ongoing challenges in securing full project financing.

Serina Therapeutics reports increased operating expenses and net loss for Q1 2026, but significant cash infusion from financing activities bolsters liquidity.

Sangamo Therapeutics reports significant financial challenges, including a Nasdaq delisting and substantial doubt about its ability to continue as a going concern, while advancing its neurology pipeline.

National Healthcare Properties, Inc. reported a net loss of $4.28 million for Q1 2026, a significant increase from the prior year's loss, impacted by a lack of property sales and increased administrative costs.

Cycurion, Inc. reported a decrease in revenue for the first quarter of 2026 compared to the prior year, citing a planned wind-down of legacy contracts and delays in new contract starts.

Interlink Electronics reported a 15.4% increase in revenue for the first quarter of 2026, driven by strong performance in the medical and automotive sectors, alongside improved gross margins.

Inhibrx Biosciences reports Q1 2026 results, highlighting clinical trial advancements for ozekibart and INBRX-106, alongside a strengthened balance sheet through debt financing.